[go: up one dir, main page]

NO931561L - APPLICATION OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATMENT OF INFLAMMATION AND SCARS - Google Patents

APPLICATION OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATMENT OF INFLAMMATION AND SCARS

Info

Publication number
NO931561L
NO931561L NO93931561A NO931561A NO931561L NO 931561 L NO931561 L NO 931561L NO 93931561 A NO93931561 A NO 93931561A NO 931561 A NO931561 A NO 931561A NO 931561 L NO931561 L NO 931561L
Authority
NO
Norway
Prior art keywords
treatment
inhibitors
scars
inflammation
plasminogen activators
Prior art date
Application number
NO93931561A
Other languages
Norwegian (no)
Other versions
NO931561D0 (en
Inventor
Eckhard Schueler
Juergen Roemisch
Eric-Paul Paques
Gerhard Dickneite
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of NO931561D0 publication Critical patent/NO931561D0/en
Publication of NO931561L publication Critical patent/NO931561L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Inhibitorer av plasminogenaktivatorer, som urokinase, uPA eller tPA for intra- og post-operativ terapi, for behandling av skader samt for behandling og profylakse av betennelsessykdommer er beskrevet. Egnede inhibitorer er spesielt PAI-1 og PAI-2,Inhibitors of plasminogen activators, such as urokinase, uPA or tPA for intra- and post-operative therapy, for the treatment of injuries and for the treatment and prophylaxis of inflammatory diseases have been described. Suitable inhibitors are especially PAI-1 and PAI-2.

NO93931561A 1992-04-30 1993-04-29 APPLICATION OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATMENT OF INFLAMMATION AND SCARS NO931561L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4214215A DE4214215A1 (en) 1992-04-30 1992-04-30 USE OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATING INFLAMMATION

Publications (2)

Publication Number Publication Date
NO931561D0 NO931561D0 (en) 1993-04-29
NO931561L true NO931561L (en) 1993-11-01

Family

ID=6457814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93931561A NO931561L (en) 1992-04-30 1993-04-29 APPLICATION OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATMENT OF INFLAMMATION AND SCARS

Country Status (16)

Country Link
EP (1) EP0567816A1 (en)
JP (1) JPH069425A (en)
KR (1) KR930021179A (en)
CN (1) CN1080873A (en)
AU (1) AU3822993A (en)
CA (1) CA2095207A1 (en)
CZ (1) CZ76893A3 (en)
DE (1) DE4214215A1 (en)
HU (1) HUT65755A (en)
IL (1) IL105521A0 (en)
MX (1) MX9302519A (en)
NO (1) NO931561L (en)
PL (1) PL298748A1 (en)
SK (1) SK41593A3 (en)
UY (1) UY23572A1 (en)
ZA (1) ZA933023B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
GB2271507A (en) * 1992-09-04 1994-04-20 Summit Technology Ireland Bv Compositions containing plasmin activity inhibitors
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
ATE339975T1 (en) * 1993-07-19 2006-10-15 Angiotech Pharm Inc ANTI-ANGIOGENIC STENT AND METHOD FOR THE PRODUCTION THEREOF
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
CN1299286A (en) * 1998-04-01 2001-06-13 澳洲生物科技公司 Use of protease inhibitors for treating skin wounds
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
EP1173198B1 (en) * 1999-04-29 2003-11-19 Ista Pharmaceuticals, Inc Use of a determined hyaluronidase to eliminate corneal scars, opacification and haze
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
JP3690720B2 (en) 1999-09-14 2005-08-31 インターナショナル・ビジネス・マシーンズ・コーポレーション Client server system, object pooling method, and storage medium
AU1123001A (en) 1999-10-27 2001-05-08 Alexandra Lucas Compositions and methods for preventing and treating transplant rejection
JP2001247458A (en) * 2000-03-08 2001-09-11 Hamari Chemicals Ltd Therapeutic agent for diabetes comprising zinc tranexmate compound
WO2002026245A2 (en) 2000-09-29 2002-04-04 Zhong Z Robert Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
IL155107A0 (en) 2000-10-16 2003-10-31 Conor Medsystems Inc Expandable medical device for delivery of beneficial agent
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
AT500019B1 (en) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm USE IN VITRO OF THE TRANSCRIPTION FACTOR NAK-1 OR NAK-1 REGULATED GENES FOR THE DIAGNOSIS OF INFLAMMATORY AND MALIGNIC DISEASES
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
BRPI0906167A2 (en) * 2008-01-21 2018-05-22 Dermadis S A Serine protease inhibitor use in the treatment of skin diseases.
TWI763960B (en) * 2017-12-15 2022-05-11 大陸商深圳瑞健生命科學研究院有限公司 Method and medicine for preventing or treating osteoarthritis
CN118557734B (en) * 2024-07-24 2024-11-22 中山大学中山眼科中心 Application of SERPINB2 inhibitor in the preparation of drugs for treating wet age-related macular degeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829523A1 (en) * 1988-08-31 1990-03-01 Behringwerke Ag USE OF PLASMINOGEN ACTIVATOR INHIBITOR (PAI-2) FOR IMMUNE SUPPRESSION
EP0458937B1 (en) * 1989-12-20 1997-08-13 Biotech Australia Pty. Limited Variants of pai-2
EP0451130A3 (en) * 1990-04-05 1992-08-05 Baltimore Biotech, Inc. Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization

Also Published As

Publication number Publication date
UY23572A1 (en) 1993-05-04
CN1080873A (en) 1994-01-19
JPH069425A (en) 1994-01-18
CA2095207A1 (en) 1993-10-31
AU3822993A (en) 1993-11-04
HU9301272D0 (en) 1993-07-28
EP0567816A1 (en) 1993-11-03
CZ76893A3 (en) 1994-01-19
SK41593A3 (en) 1993-11-10
PL298748A1 (en) 1993-12-27
DE4214215A1 (en) 1993-11-04
ZA933023B (en) 1994-10-31
NO931561D0 (en) 1993-04-29
IL105521A0 (en) 1993-08-18
MX9302519A (en) 1993-10-01
KR930021179A (en) 1993-11-22
HUT65755A (en) 1994-07-28

Similar Documents

Publication Publication Date Title
NO931561L (en) APPLICATION OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATMENT OF INFLAMMATION AND SCARS
ATE277612T1 (en) ARYL UREA DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY OR IMMUNOMODULATORY DISEASES
DK0719154T3 (en) Activated factor VIII as a therapeutic agent and method for treating factor VIII deficiency
Bunning et al. Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes
ZA964608B (en) Kunitz type plasma kallikrein inhibitors.
NO303116B1 (en) Compounds that can be used for the treatment of allergic diseases and inflammatory diseases, their use, and pharmaceutical preparations containing them
NO961888D0 (en) Peptidyl compounds and their therapeutic use as inhibitors of metal proteinases
CA2120303A1 (en) Cyclic adhesion inhibitors
UA26213C2 (en) MEANS FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS AND PHARMACEUTICAL COMPOSITION AND THEIR BASES
DK0668769T3 (en) Oak barley extract-related synthetic compositions and methods for their use
PT705100E (en) THERAPEUTIC SUBSTITUTED GUANIDINS
DK0662948T3 (en) 2-Amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and / or kynurenine-3-hydroxylase inhibitory effect
ATE38036T1 (en) BENZOTHIOPHENE DERIVATIVES AS BRONCHODILATORS.
ES2088128T3 (en) ACAT INHIBITOR AMINOSULFONILUREAS.
MXPA94009086A (en) Therapeutic substituted guanidines.
NO983906D0 (en) Use of carbonic anhydrase inhibitors for the treatment of macular edema
NO983295L (en) Control of healing process
AU2861389A (en) Disubstituted pyridines
ES2139674T3 (en) METHOD TO TREAT THE SYMPTOMATOLOGY OF PREMENSTRUAL SYNDROME WITH VITAMIN D OR VITAMIN D AND CALCIUM.
HUP9901353A2 (en) Use of an ace-inhibitor for producing pharmaceutical composition suitable for treating dyspeptic symptoms
DE59107336D1 (en) Oligosaccharide derivatives and their use in medicinal products
WO2003053999A3 (en) Selective arylguanidine peptides as urokinase inhibitors
IT1289154B1 (en) ISOFLAVONE DERIVATIVES THEIR PREPARATION AND THEIR THERAPEUTIC USE
DE68916958D1 (en) TOPICALLY APPLIED GOLD ORGANO COMPLEX.
ATE189395T1 (en) USE OF PROTEASE NEXIN-I AS AN ANTI-INFLAMMATORY AGENT